Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A Phase II, 12-Week Study of ISIS 14083, An Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C

A Phase II, 12-Week Study of ISIS 14083, An Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C. Hepatology. 2002; 36(4):362A.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.